A light-emitting device includes: a first electrode; a second electrode facing the first electrode; an interlayer between the first electrode and the second electrode and including an emission layer; and an organometallic compound of Formula 1:

##STR00001##

wherein, in Formula 1, the variables are described herein.

Metal-organic framework materials (MOFs) are highly porous entities comprising a multidentate organic ligand coordinated to multiple metal centers, typically as a coordination polymer. MOFs may comprise a plurality of metal centers, and a multidentate organic ligand coordinated via at least two binding sites to the plurality of metal centers to define an at least partially crystalline network structure having a plurality of internal pores, and in which the multidentate organic ligand comprises first and second binding sites bridged together with a third binding site comprising a diimine moiety. The multidentate organic ligand may comprise a reaction product of a vicinal dicarbonyl compound and an amine-substituted salicylic acid to define the first, second and third binding sites. Particular MOFs may comprise 5,59′-(((1E,2E)-ethane-1,2-diylidene)bis-(azaneylylidene))bis(2-hydroxybenzoic acid) as a multidentate organic ligand.

Metal-organic frameworks (MOFs) comprising amines on the organic linker can be used for cell targeting. In particular, primary amine groups represent one of the most versatile chemical moieties for conjugation to biologically relevant molecules, including antibodies and enzymes. Different chemical conjugation schemes can be used to conjugate biological molecules to the amino functionality on the organic linker. For example, carbodiimide chemistry can be used to link a primary amine to available carboxyl groups on the protein. For example, sulfhydryl crosslinking chemistry can be used via Traut's reagent scheme. As a demonstration of the invention, the ability of EpCAM antibody-targeted MOFs to bind to a human epithelial cell line (A549), a common target for imaging studies, was confirmed with confocal microscopy.

The present invention relates to inorganic-organic hybrid compounds for use in medicine or for use as medication, consisting of an inorganic metal cation and an organic platinum-containing cytostatic anion, in particular also a cisplatin derivative.

The present invention relates to an improved process for the preparation of 2,2′,2″-(10-((2R,3S)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid, gadolinium (III) with iron metal content less than 5 ppm and free gadolinium content less than 10 ppm, which is represented by the formula (1). The present invention further relates to an improved process for the preparation of calcium complex of 10-(2,3-Dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclo decane-1,4,7-triacetic acid known as Calcobutrol (1a) and its sodium salt of formula (1b) with purity greater than 98.0%.

##STR00001##

Monomeric bimetal hydroxycitric acid (HCA) compounds are provided. The subject compounds include a divalent metal (X) bonded to the carboxylic acids of C2 and C3 and a monovalent metal (Y) bonded to the carboxylic acid of C1. Also provided are methods of preparing the subject compounds from a dimeric starting material (e.g., X.sub.3(HCA).sub.2) which include acidifying the dimer to produce a monomeric intermediate which is subsequently neutralized with YOH base. Methods of alleviating at least one symptom associated with a target disease or condition in a subject are provided. Also provided are compositions including the subject monomeric bimetal HCA compounds which find use in a variety of therapeutic applications.

Methods of synthesizing crystalline metal-organic frameworks (MOFs) comprising polytopic organic linkers and cations, where each linker is connected to two or more cations, are provided. In the disclosed methods, the linkers are reacted with a compound of formula M.sub.nX.sub.m, where M is cationic Be, Mg, Ca, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Zr, Nb, Mo, Ru, Rh, Pd, Cd, or Hf, X is anionic, n and m are integers. The reacting is buffered by a buffer devoid of metal coordinating functionality when the pKa of the anion is below a threshold related to the lowest pKa of the linker. The reacting is optionally not buffered when the pKa of the anion is at or above this threshold. The disclosed methods lead to product phase MOF in which crystal growth is controlled leading to control over molecular diffusion.

Flow batteries can include a first half-cell containing a first aqueous electrolyte solution, a second half-cell containing a second aqueous electrolyte solution, and a separator disposed between the first half-cell and the second half-cell, The first aqueous electrolyte solution contains a first redox-active material, and the second aqueous electrolyte solution contains a second redox-active material. At least one of the first redox-active material and the second redox-active material is a nitroxide compound or a salt thereof. Particular nitroxide compounds can include a doubly bonded oxygen contained in a ring bearing the nitroxide group, a doubly bonded oxygen appended to a ring bearing the nitroxide group, sulfate or phosphate groups appended to a ring bearing the nitroxide group, various heterocyclic rings bearing the nitroxide group, or acyclic nitroxide compounds.

A hypergolic metal organic framework material for producing a hypergol when combined with an oxidizer, comprising a general structure M1-L-M2, wherein L is an aromatic organic linker comprising one or more unsaturated substituents, and wherein M1 and M2 are same or different metal cations.

Methods of preparing and using a metal-organic framework (MOF) are provided herein, including methods of using an MOF comprising a repeat unit of the formula [ML].sub.n, wherein M is a divalent metal ion and L is a ligand of the formula:

##STR00001##

The MOFs provided herein may be used in the separation of two or more molecules from each other. In some embodiments, the molecules are ethylene and ethane. In some embodiments, UTSA-280 may be synthesized from calcium oxide (CaO) or calcium hydroxide (Ca(OH).sub.2) and squaric acid (SA) through mechanochemical synthesis.